Company intelligence / Profile preview

Medios Technologies

Singapore, Central Singapore, Singaporepmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

The company has developed an AI-powered platform that enables any physician to grade fundus images for diabetic retinopathy instantly and without the need for a specialist. The technology provides immediate results and aims to facilitate early detection of diabetic retinopathy to prevent vision loss. It has been developed in collaboration with leading hospitals and claims clinical safety but appears to be in early access or limited release as of the latest updates.

Therapeutic areas: Ophthalmology
Modalities: DeviceArtificial intelligence software (for image analysis)
Industry: Medical Imaging

Partnerships

Collaborations with leading hospitals for clinical validation

Beyond the preview

Go deeper on Medios Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medios Technologies.

Explore the full profile